Education
About Us
Working with TipRanks
Follow Us
Radiopharm Theranostics Limited Sponsored ADR (RADX)
NASDAQ:RADX
RESEARCH TOOLSreports
Total Valuation
Radiopharm Theranostics Limited Sponsored ADR has a market cap or net worth of $37.00M. The enterprise value is ―.
Market Cap$37.00M
Enterprise Value―
Share Statistics
Radiopharm Theranostics Limited Sponsored ADR has 7,883,165 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,883,165
Owned by Insiders―
Owned by Institutions4.35%
Financial Efficiency
Radiopharm Theranostics Limited Sponsored ADR’s return on equity (ROE) is -1.71 and return on invested capital (ROIC) is -67.38%.
Return on Equity (ROE)-1.71
Return on Assets (ROA)-0.67
Return on Invested Capital (ROIC)-67.38%
Return on Capital Employed (ROCE)-0.67
Revenue Per Employee10.00T>
Profits Per Employee―
Employee Count―
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Radiopharm Theranostics Limited Sponsored ADR is ―. Radiopharm Theranostics Limited Sponsored ADR’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value1.22
Price to FCF0.00
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Radiopharm Theranostics Limited Sponsored ADR had revenue of 299.23K and earned -47.95M in profits. Earnings per share was -37.22.
Revenue299.23K
Gross Profit299.23K
Operating Income-36.62M
Pretax Income-47.85M
Net Income-47.95M
EBITDA-44.08M
Earnings Per Share (EPS)-37.22
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Radiopharm Theranostics Limited Sponsored ADR pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.34
52-Week Price Change12.74%
50-Day Moving Average4.68
200-Day Moving Average4.73
Relative Strength Index (RSI)59.32
Average Volume (3m)21.36K
Important Dates
Radiopharm Theranostics Limited Sponsored ADR upcoming earnings date is Sep 25, 2025, TBA (Not Confirmed).
Last Earnings DateFeb 28, 2025
Next Earnings DateSep 25, 2025
Ex-Dividend Date―
Financial Position
Radiopharm Theranostics Limited Sponsored ADR as a current ratio of 1.30, with Debt / Equity ratio of ―
Current Ratio1.30
Quick Ratio1.30
Debt to Market Cap0.00
Net Debt to EBITDA0.42
Interest Coverage Ratio-56.96
Taxes
In the past 12 months, Radiopharm Theranostics Limited Sponsored ADR has paid 96.36K in taxes.
Income Tax96.36K
Effective Tax Rate>-0.01
Enterprise Valuation
Radiopharm Theranostics Limited Sponsored ADR EV to EBITDA ratio is -232.12, with an EV/FCF ratio of -445.36.
EV to Sales34.20K
EV to EBITDA-232.12
EV to Free Cash Flow-445.36
EV to Operating Cash Flow0.00
Balance Sheet
Radiopharm Theranostics Limited Sponsored ADR has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt―
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share-$0.06
Margins
Gross margin is ―, with operating margin of -12238.44%, and net profit margin of -16024.28%.
Gross Margin―
Operating Margin-12238.44%
Pretax Margin-15992.07%
Net Profit Margin-16024.28%
EBITDA Margin-14732.44%
EBIT Margin-15777.22%
Analyst Forecast
The average price target for Radiopharm Theranostics Limited Sponsored ADR is $20.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$20.00
Price Target Upside283.14% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―